Does Medicaid Cover GLP-1s in 2026? Coverage by Situation

Last updated: November 2026 · Written by Ash Heleka

Medicaid covers GLP-1 medications like Ozempic and Mounjaro for type 2 diabetes in every state. For weight loss alone, KFF counted 13 state Medicaid programs covering drugs like Wegovy and Zepbound in January 2026, down from 16 in October 2025, and Massachusetts dropped coverage in July 2026. The answer depends less on which state you live in and more on why the drug is being prescribed, which is what this guide breaks down.

Most articles on this topic give you a state list that goes stale within months. Four states dropped weight loss coverage between October 2025 and January 2026, and Massachusetts followed in July 2026. So instead of a state table, I am going to walk through coverage by situation, because your diagnosis matters more than your zip code. Two of these situations get you covered in every state, and almost nobody writing about this mentions them.

Does Medicaid Cover Ozempic and Mounjaro for Type 2 Diabetes?

Yes, in every state. Federal Medicaid rules require states to cover outpatient drugs from manufacturers in the Medicaid rebate program for their FDA-approved uses, and KFF lists diabetes as a required coverage category while weight loss is optional. So Ozempic, Mounjaro, Rybelsus, and Trulicity are covered by every state Medicaid program when prescribed for type 2 diabetes.

Covered does not mean automatic. Most states put GLP-1s behind prior authorization, and many require step therapy, meaning you try metformin or another cheaper drug first. Some states also require a recent A1C reading. Your prescriber handles the paperwork, but expect the approval to take days to a few weeks. If you want to understand how diabetes and weight loss prescribing differ, I cover that in GLP-1 for type 2 diabetes vs weight loss.

Does Medicaid Cover Wegovy or Zepbound for Weight Loss?

Only in a minority of states, and the list is shrinking fast. Federal law treats weight loss drugs as an optional category that states can exclude, and most do. According to KFF’s January 2026 analysis, 13 state Medicaid programs covered GLP-1s for obesity treatment as of January 2026, down from 16 in October 2025 after California, New Hampshire, Pennsylvania, and South Carolina cut coverage.

It kept shrinking through 2026. MassHealth ended coverage of GLP-1s for weight loss on July 1, a change officials said affects at least 22,000 people. KFF also noted that Utah’s funding for this coverage was limited to fiscal year 2026, which ended June 30. We could not find a current official count, so check your own state’s preferred drug list.

The reason is money. KFF reports that gross Medicaid spending on GLP-1s grew from about $1 billion in 2019 to nearly $9 billion in 2024, with prescriptions up sevenfold. States facing budget pressure cut the optional category first, and weight loss coverage is the optional category.

If your state does cover weight loss GLP-1s, expect strict conditions. Typical requirements include a BMI threshold, documented participation in a lifestyle program, and reauthorization every few months with proof you are losing weight.

Which Situations Get GLP-1 Coverage in Every State?

Three diagnoses require Medicaid coverage no matter where you live, because they are FDA-approved indications outside the weight loss exclusion. This is the part most coverage articles miss, and it changes the answer for a lot of people.

The heart disease and sleep apnea rows are the ones worth a close look. If you have established cardiovascular disease with obesity or overweight, Wegovy is FDA-approved to reduce the risk of major cardiovascular events such as heart attack and stroke. That indication is not weight loss, so KFF lists it as required coverage. Same logic for Zepbound if you have moderate to severe obstructive sleep apnea and obesity.

This is not a loophole you can talk your way into. You need the actual diagnosis documented, and prior authorization still applies. But if you have untreated sleep apnea and have been assuming Medicaid would never pay for a GLP-1, a sleep study might change your situation entirely. Bring it up with your doctor. I wrote a separate guide on how to talk to your doctor about GLP-1 medications if you want a script.

What Is the BALANCE Model and Will It Expand Coverage?

BALANCE is a voluntary CMS pilot, announced in December 2025, that lets state Medicaid programs cover GLP-1s for obesity at negotiated prices starting as early as May 2026. Per CMS and KFF’s May 2026 breakdown, states can join on a rolling basis through January 1, 2027, and the model covers Wegovy, Ozempic, Rybelsus, Mounjaro, the oral pill Foundayo, and the KwikPen formulation of Zepbound.

Two caveats matter. First, participation is voluntary on all sides. Your state has to opt in, and it can drop out later. Second, CMS says BALANCE is not launching in Medicare in 2027. Medicare enrollees instead have a separate short-term Medicare GLP-1 Bridge that CMS lists as running from July 1, 2026, to December 31, 2027. My read is that BALANCE gives budget-strapped states a cheaper path back to coverage, but I would not build a treatment plan around a state joining. Watch your state Medicaid agency’s announcements rather than national headlines. Medicare has its own separate rules, which I cover in the Medicare GLP-1 coverage guide.

How Much Will You Pay If Medicaid Covers Your GLP-1?

Very little. Federal rules cap Medicaid drug copays at nominal amounts. Medicaid.gov’s cost sharing table lists $4 for preferred drugs and $8 for non-preferred drugs, with higher cost sharing allowed for some enrollees above 150% of the poverty level. That makes Medicaid coverage, when you can get it, the cheapest way to be on these medications. It also makes losing coverage hard, because the jump from a few dollars to cash-pay prices is steep.

One thing that surprises people is that manufacturer savings cards cannot soften that cliff. The Lilly Zepbound savings card terms exclude anyone enrolled in Medicaid, Medicare, TRICARE, VA or another government-funded program. Novo Nordisk’s Wegovy offer lets government-insured patients use it only at the self-pay price. That applies even if Medicaid is denying the specific drug. More on those programs in the copay cards and patient assistance guide.

What If Your State Does Not Cover GLP-1s for Weight Loss?

You have three realistic paths, and I have watched people work through all of them since I started tracking this market while on Mounjaro myself.

Path 1, check the required-coverage indications first. Before paying cash, rule out the diagnoses in the table above. A sleep study or cardiology workup costs Medicaid far less than a year of GLP-1 therapy, and either one can convert you from “excluded” to “covered in every state.”

Path 2, appeal a denial if you are in a covering state. If your state covers weight loss GLP-1s and you were denied on prior authorization, appeal. Denials often turn on missing documentation rather than eligibility. I built a template for this in the insurance appeal letter guide.

Path 3, cash pay. As of Nov 4, 2026, LillyDirect lists Zepbound at $299 a month for the 2.5 mg starting dose and $399 for 5 mg. Higher doses are $449 if you refill within 45 days and up to $699 if you don’t. NovoCare lists Wegovy pens at $199 a month for the first two fills of the starting doses for new patients through December 31, 2026, then $349, and Wegovy pills from $149. None of these require insurance.

Some telehealth companies also sell compounded semaglutide for less. The FDA declared the semaglutide shortage resolved in February 2025, and it warns that compounded drugs are not FDA approved and are not reviewed for safety, effectiveness or quality. Talk to your prescriber before choosing one. The full price rundown is in my cheapest GLP-1 online guide.

The Bottom Line

Whether Medicaid covers your GLP-1 comes down to the diagnosis on the prescription. Type 2 diabetes, cardiovascular disease with Wegovy, and obstructive sleep apnea with Zepbound get required coverage in every state. Obesity alone got coverage in only 13 states in January 2026, and Massachusetts has dropped out since. If you are in the excluded majority, work the diagnosis angle first, then the BALANCE model if your state joins, then compare manufacturer cash-pay prices. Start with our provider comparison to see current verified prices side by side.

Frequently Asked Questions

Does Medicaid cover Ozempic for weight loss?

No. Ozempic is FDA-approved for type 2 diabetes, not weight loss, so Medicaid covers it only with a diabetes diagnosis. Prescribing it off-label for weight loss will almost always be denied. Wegovy is the semaglutide product approved for weight management, and its coverage depends on your state.

Which states cover Wegovy or Zepbound for weight loss under Medicaid?

KFF counted 13 state Medicaid programs covering GLP-1s for obesity treatment in January 2026, down from 16 in October 2025, and Massachusetts ended coverage in July 2026. Because states keep dropping coverage, check your state Medicaid agency’s preferred drug list directly rather than relying on a published state list.

Does Medicaid cover Zepbound for sleep apnea?

Yes, in every state. The FDA approved Zepbound for moderate to severe obstructive sleep apnea in adults with obesity in December 2024, and that indication falls under required Medicaid drug coverage rather than the optional weight loss category. You need a documented OSA diagnosis, usually from a sleep study, and prior authorization still applies.

Can I use a Wegovy or Zepbound savings card if I have Medicaid?

No. Both the Novo Nordisk and Eli Lilly savings card programs exclude anyone enrolled in Medicaid, Medicare, or other government insurance, even if your plan denies the drug. Novo Nordisk lets government-insured patients pay the NovoCare self-pay price. LillyDirect self-pay prices for Zepbound start at $299 a month as of Nov 4, 2026.

What is the BALANCE model?

BALANCE is a voluntary CMS pilot announced in December 2025 that lets state Medicaid programs cover GLP-1s for obesity at negotiated prices, with state participation starting May 2026. States opt in on a rolling basis through January 1, 2027, and can later withdraw. CMS says BALANCE is not launching in Medicare in 2027.

This article is for informational purposes only and does not constitute medical advice. Coverage rules and pricing are based on publicly available data as of November 4, 2026 and may change. Always verify coverage with your state Medicaid agency and consult a qualified healthcare provider before starting any medication. ClearMetabolic may earn a commission through provider links on this page. See our full disclosure.

Related

Guides:

• Medicare Coverage · Insurance Coverage · Without Insurance
• Copay Cards and Patient Assistance · Insurance Appeal Letter Template · Cash Pay vs Insurance
• Cheapest GLP-1 Online · Does TRICARE Cover GLP-1s? · T2D vs Weight Loss Dosing

Medications: Ozempic · Wegovy · Mounjaro · Zepbound

Compare: All Providers · All Guides

What we checked

This AI-assisted public-source desk check reviewed KFF’s Medicaid GLP-1 analysis, CMS’s BALANCE model page, Medicaid.gov’s cost sharing rules, WBUR’s report on the MassHealth change, the Wegovy label, FDA compounding notices, and the LillyDirect, Zepbound savings and NovoCare price pages on November 4, 2026. This is not a clinical review and it is not medical advice. Prices and policies change, so confirm them with the provider or your prescriber before you act.